- REC–4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)
- After 12 weeks [...] Read more »
Miltenyi Biomedicine stellt die Primäranalyse der zulassungsrelevanten DALY-2-EU-Studie zur Zweitlinientherapie des rezidivierten/refraktären großzelligen B-Zell-Lymphoms auf der 67. Jahrestagung der American Society of Hematology (ASH) vor
- Die Ergebnisse der DALY 2–EU–Studie zeigen, dass Zamtocabtagen Autoleucel (Zamto–cel) bei Patienten mit rezidiviertem/refraktärem [...] Read more »
À l’occasion de la 67e réunion annuelle de l’American Society of Hematology (ASH), Miltenyi Biomedicine présente l’analyse primaire de l’essai pivot DALY 2-EU pour le traitement de seconde ligne du lymphome à grandes cellules B en rechute ou réfractaire
- Les résultats de l’essai DALY 2–EU révèlent que le zamtocabtagene autoleucel (zamto–cel) présente une [...] Read more »
Miltenyi Biomedicine divulga análise primária do estudo principal do DALY 2-EU para linfoma de células B grandes recidivante/refratário de segunda linha na 67ª Reunião Anual da Sociedade Americana de Hematologia (ASH)
- Os resultados do DALY 2–UE mostram que o autoleucel de zamtocabtageno (zamto–cel) demonstrou superioridade clinicamente significativa em [...] Read more »
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
- DALY 2–EU results show zamtocabtagene autoleucel (zamto–cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B–cell lymphoma [...] Read more »
Sabin Vaccine Institute’s Investigational Marburg Vaccine Delivered to Ethiopia for Outbreak Response
WASHINGTON, Dec. 04, 2025 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute (Sabin) has sent more than 640 doses of its investigational cAd3–Marburg Vaccine to Ethiopia to support the [...] Read more »
Enlivex annonce un placement privé de 212 000 000 $ pour lancer la première stratégie au monde de trésorerie d’actifs numériques sur les marchés prédictifs, via l’accumulation de jetons RAIN, et la nomination de Matteo Renzi, ancien Premier ministre italien, à son conseil d’administration
– À la clôture du placement privé, Enlivex adoptera la première stratégie au monde de trésorerie d’actifs numériques sur les marchés prédictifs [...] Read more »
Enlivex Anuncia Colocação Privada de US $212.000.000 para Início da Primeira Estratégia de Previsão de Mercados de Tesouro de Ativos Digitais do Mundo, via Acumulação de tokens RAIN, e a Nomeação de Matteo Renzi, Ex-Primeiro-Ministro da Itália, para seu Conselho
– Após o fechamento da colocação privada, a Enlivex adotará a primeira estratégia de tesouro de ativos digitais de token de previsão RAIN do mundo, por meio do acúmulo [...] Read more »
Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board
– Upon the closing of the private placement, Enlivex will adopt the world’s first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation.
Read more »
Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition
HAIFA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical–stage biotechnology company developing novel therapies to treat [...] Read more »